Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13158: Variant p.Cys105Trp

FAS-associated death domain protein
Gene: FADD
Feedback?
Variant information Variant position: help 105 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Tryptophan (W) at position 105 (C105W, p.Cys105Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In IEHDCM; reduced folding stability as measured by differential scanning calorimetry of the mutant protein; impairs interaction with FAS. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 105 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 208 The length of the canonical sequence.
Location on the sequence: help GAAAGAAPGEEDLCAAFNVI C DNVGKDWRRLARQLKVSDTK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GAAAGAAPGEEDLCAA-----------------------FNVICDNVGKDWRRLARQLKVSDTK

Mouse                         GTATAAPPGEADLQVA-----------------------FD

Bovine                        GAAGGAAPEDRDLRAA-----------------------ME

Drosophila                    PASQNAQPSVSELAAAVPPTAIQNYATPAAFTDHKRTMVFK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 208 FAS-associated death domain protein
Domain 97 – 181 Death
Glycosylation 117 – 117 (Microbial infection) N-beta-linked (GlcNAc) arginine
Mutagenesis 117 – 117 R -> A. Abolished GlcNAcylation by E.coli NleB1.
Mutagenesis 117 – 117 R -> E. Loss of interaction with FAS.
Mutagenesis 121 – 121 V -> N. Loss of interaction with FAS.
Mutagenesis 123 – 123 D -> R. Strongly decreased interaction with FAS.
Helix 97 – 107



Literature citations
Whole-exome-sequencing-based discovery of human FADD deficiency.
Bolze A.; Byun M.; McDonald D.; Morgan N.V.; Abhyankar A.; Premkumar L.; Puel A.; Bacon C.M.; Rieux-Laucat F.; Pang K.; Britland A.; Abel L.; Cant A.; Maher E.R.; Riedl S.J.; Hambleton S.; Casanova J.L.;
Am. J. Hum. Genet. 87:873-881(2010)
Cited for: FUNCTION IN INTERFERON-MEDIATED IMMUNITY; INTERACTION WITH FAS; VARIANT IEHDCM TRP-105; CHARACTERIZATION OF VARIANT IEHDCM TRP-105;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.